1. Addy CL, Longini IM, Haber M (1991). A generalized stochastic model for the analysis of infectious disease final size data. Biometrics 47, 961-974.
  2. Anderson RM, May RM (1991). Infectious Diseases in Humans: Dynamics and Control. Oxford University Press.
  3. Athreya KB, Ney PE (1972). Branching Processes. New York-Heidelberg: Springer-Verlag.
  4. Australian Bureau of Transport and Regional Economics. Australian Domestic Airline Activity. Aviation Statistics Domestic Monthly 106 October 2005 Available from: http://www.btre.gov.au/statistics/aviation/domestic.aspx
  5. Bailey NTJ (1975). The Mathematical Theory of Infectious Diseases and its Application. London: Griffin.
  6. Becker NG, Glass K, Li Z, Aldis G (2005). Controlling emerging infectious diseases like SARS. Mathematical Biosciences 193, 205-221.
  7. Becker NG, Glass K (2005). The impact of imported infection. (In press, as a peer-reviewed chapter in a book.)
  8. Crosby AW Jr (1976). Epidemic and Peace, 1918. Connecticut: Greenwood Press.
  9. Davis LE, Caldwell GG, Lynch RE, Bailey RE, Chin TD (1970). Hong Kong influenza: the epidemiologic features of a high school family study analyzed and compared with a similar study during the 1957 Asian influenza epidemic American Journal of Epidemiology 92, 240-247.
  10. Day T, Park A, Madras N, Gumel A, Jianhong W (2006). When is quarantine a useful control strategy for emerging infectious diseases? American Journal of Epidemiology 163, 479-485.
  11. Edmunds, WJ, O'Callaghan, CJ, Nokes, DJ (1997). Who mixes with Whom? A Method to Determine the Contact Patterns of Adults That May Lead to the Spread of Airborne Infections. Proceedings: Biological Sciences 264, 949-957.
  12. Elveback LR, Fox JP, Ackerman E, Langworthy A, Boyd M, Gatewood L (1976). An Influenza simulation model for immunization studies. American Journal of Epidemiology 103, 152-165.
  13. Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS (2005). Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437, 209-214.
  14. Fraser C, Riley S, Anderson RM, Ferguson NM (2004). Factors that make an infectious disease outbreak controllable. Proceedings of the National Academy of Science 101, 6146–6151.
  15. Fox JP, Hall CE, Cooney MK, Foy HM (1982). Influenza virus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. American Journal of Epidemiology 116, 212-227.
  16. Gamage B, Moore D, Copes R, Yassi A, Bryce E (2005). Protecting health care workers from SARS and other respiratory pathogens: a review of the infection control literature. American Journal of Infection Control 33, 114-121.
  17. Gani R, Hughes H, Fleming D, Griffin T, Medlock J, Leach S (2005). Potential impact of antiviral drug use during influenza pandemic. Emerging Infectious Diseases 11, 1355-1362.
  18. Glass K, Becker NG (2005). Evaluation of measures to reduce international spread of SARS. Epidemiology and Infection (in press).
  19. Green LE, Medley GF (2002).  Mathematical modelling of the foot and mouth disease epidemic of 2001: Strengths and weaknesses. Research in Veterinary Science 73, 201-205.
  20. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE (1998). Local and systemic cytokine responses during experimental human influenza A virus infection.  Relation to symptom formation and host defense. Journal of Clinical Investigation. 101, 643-649.
  21. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, Straus SE (1999). Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza. Journal of the American Medical Association 282, 1240-1246.
  22. Hayden RG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. New England Journal of Medicine 341, 1335-1343.
  23. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK (1996) Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. Journal of the American Medical Association 275, 295-299.
  24. Jordan WS Jr, Denny FW Jr, Badger GF, Curtiss C, Dingle JH, Oseasohn R, et al. (1958). A study of illness in a group of Cleveland families, XVII. The occurrence of Asian influenza. American Journal of Hygiene 68, 190-212.
  25. King GE, Markowitz LE, Patriarca PA, Dales LG (1991). The clinical efficacy of measles-vaccine during the 1990 measles epidemic. Pediatric Infectious Disease Journal 10, 883-888.
  26. Loeb M, McGeer A, Henry B, Ofner M, Rose D, Hlywka T, Levie J, McQueen J, Smith S, Moss L, Smith A, Green K, Walter SD (2004). SARS among critical care nurses, Toronto. Emerging Infectious Diseases 10, 251-255.
  27. Longini IM, Halloran ME, Nizam A, Yang Y (2004). Containing pandemic influenza with antiviral agents. American Journal of Epidemiology 159, 623-633.
  28. Longini IM, Koopman J (1982). Household and community transmission parameters from final distributions of infections in households. Biometrics 38, 115-126.
  29. Longini IM, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DAT, Halloran ME (2005). Containing pandemic influenza at the source. Science 309, 1083-1087.
  30. Mantle J, Tyrrell DA (1973). An epidemic of influenza on Tristan da Cunha. Journal of Hygiene (London) 71, 89-95.
  31. McCracken K, Curson P (2003). Flu downunder: a demographic and geographical analysis of the 1919 epidemic in Sydney, Australia. Pages 110–131 in The Spanish Influenza Pandemic of 1918–19. Phillips H and Killingray D (Eds). Routledge, London, 357p.
  32. Meltzer MI, Cox NJ, Fukuda K. (1999). Modeling the economic impact of pandemic influenza in the United States: Implications for setting priorities for intervention. Emerging Infectious Diseases. 5,659-671.
  33. Mills CE, Robins JM, Lipsitch M (2004). Transmissibility of 1918 pandemic influenza. Nature 432, 904-906.
  34. Monto AS, Koopman JS, Longini IM (1985). Tecumseh study of illness:XIII, Influenza infection and disease, 1976-1981. American Journal of Epidemiology 121, 811-822.
  35. Nguyen-Van-Tam JS, Hampson AW (2003). The epidemiology and clinical impact of pandemic influenza. Vaccine 21, 1762-1768.
  36. O'Neill PD, Balding DJ, Becker NG, Eerola M, Mollison D (2000). Analyses of infectious disease data from household outbreaks by Markov chain Monte Carlo methods. Applied Statistics 49, 517-542.
  37. Ramsay M, Gay N, Miller E, Rush M, White J, Morgan-Capner P (1994). The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. Commun Dis Rep 4, R141-6.
  38. Riley S,  Fraser C, Donnelly CA, Ghani AC, Abu-Raddad LJ, Hedley AJ, Leung GM, Ho L-M, Lam T-H, Thach TQ et al.  Transmission dynamics of the etiological agent of SARS in Hong Kong: Impact of Public Health Interventions, Science 300, 1961-1966.
  39. Roberts MG, Tobias MI (2000). Predicting and preventing measles epidemics in New Zealand: Application of a mathematical model. Epidemiology and Infection 124, 279-287.
  40. Samaan G, Patel M, Spencer J, Roberts L (2004). Border screening for SARS in Australia : what has been learnt? Medical Journal of Australia 180, 220–223.
  41. Spicer CC, Lawrence CJ (1984). Epidemic influenza in Greater London. Journal of Hygiene (London) 93, 105-112.
  42. Tourism Victoria. Domestic Visitation to Regions of Victoria year ending September 1999-2005 .  2005 Available from: http://www.tourism.vic.gov.au/images/assets/All_PDFs/research/dec05/domestic-visitation-to-regions-of-victoria-year-ending-sept%201999-2005.pdf
  43. Tourism New South Wales. Travel to Sydney Year ended September 2005.  Available from: http://corporate.tourism.nsw.gov.au/corporatelive/downloads/research/sydney%20sep%202005.pdf
  44. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N,Ward P, Mills RG (2000). Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. Journal of the American Medical Association 283, 1016-1024.
  45. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K (2003). Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technology Assessment 7, 1-170.
  46. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P,Oxford JS (2001). Effectiveness of oseltamivir in preventing influenza in household contacts. Journal of the American Medical Association 285, 748-856.
  47. WHO Writing Group (2006). Nonpharmaceutical interventions for pandemic influenza, international measures. Emerging Infectious Diseases 12, 81-87
  48. WHO Writing Group (2006). Nonpharmaceutical interventions for pandemic influenza, national and community measures. Emerging Infectious Diseases 12, 88-94.
  49. Wilder-Smith A, Goh KT, Paton NI. (2004) Experience of severe acute respiratory syndrome in Singapore: importation of cases, and defense strategies at the airport. Journal of Travel Medicine 10, 259–262.
  50. Yen M-Y, Lin YE, Su I-J, Huang F-Y, Huang F-Y, Ho M-S, Chang S-C, Tan K-H, Chen K-T, Chang H, Liu Y-C, Loh C-H, Wang L-S, Lee C-H (2006). Using an integrated infection control strategy during outbreak control to minimize nosocomial infection of severe acute respiratory syndrome among healthcare workers. Journal of Hospital Infection,  62, 195-199.

Document download

This publication is available as a downloadable document.

Using Mathematical Models to Assess Responses to an Outbreak of an Emerged Viral Respiratory Disease(PDF 873 KB)